Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health

SALT LAKE CITY, Aug. 03, 2016 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has signed a definitive agreement to acquire Assurex Health, a global leader in genetic testing for psychotropic medicine selection, for $225 million upfront with the potential for $185 million in additional performance-based milestones. Assurex generated revenue of more than $60 million and tested more than 150,000 patients in Myriad’s fiscal year 2016. The transaction is expected to close at the end of Myriad’s first quarter of fiscal year 2017. Myriad will provide financial guidance pertaining to the acquisition when the Company hosts its fourth-quarter earnings call on August 9, 2016.  A discussion on the details and strategy underlying this acquisition will be provided on a…


Link to Full Article: Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health